Why Insmed Incorporated (INSM) stock moved
Why Insmed Incorporated (INSM) rose 20.6% today, November 19, 2026
Insmed Incorporated (INSM) rose 20.6% on November 19, 2026, closing at $144.46 versus $119.80 the prior session (close-to-close, from daily closes). After Bloomberg reported that pharmaceutical giant Sanofi is exploring a potential acquisition of the company. Talks are ongoing with no guarantee of completion, but analysts estimate Insmed could command $170–$210 per share in a buyout, suggesting a 20–50% acquisition premium from the pre-announcement price. Source: FMP price data; BestStocks detection.
Insmed Incorporated (INSM) moved +20.89% from $119.50 to $144.46 on 2026-11-19 after Bloomberg reported that pharmaceutical giant Sanofi is exploring a potential acquisition of the company. Talks are ongoing with no guarantee of completion, but analysts estimate Insmed could command $170–$210 per share in a buyout, suggesting a 20–50% acquisition premium from the pre-announcement price.
What to watch next: Monitor for updates on Sanofi takeover negotiations and any competing bids; next scheduled earnings announcement is 2027-02-18.
Earlier sessions that moved INSM
- +2.6%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +2.9%Broader patient access.
- +5.2%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- +5.3%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- −4.5%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −2.9%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +15.1%Insmed reported third-quarter 2026 financial results today, posting a net loss but beating revenue estimates (Zacks). Read the October 29, 2026 analysis →
- −3.0%Following the announced departure of CFO Sara Bonstein (effective October 30, 2026) and a Wolfe Research downgrade from Outperform to Peer Perform citing slower-than-expected expansion of the addressable market for Brinsupri.
- −3.3%Insmed's CFO Sara Bonstein announced her resignation effective October 30, 2026, creating near-term leadership uncertainty just ahead of third-quarter earnings on October 29 (Zacks, Investing.com).
- −6.6%Insmed shares declined 6.6% on October 5, 2026, following the company's announcement that CFO Sara Bonstein will resign effective October 30, 2026, after nearly seven years in the role. Read the October 5, 2026 analysis →
- −4.9%Amid a combination of recent analyst price-target cuts—notably Barclays lowering its target from $237 to $207 while maintaining an Overweight rating—alongside broader profit-taking in the biotech sector and cooling short-term sentiment on high-multiple rare-disease names.
- −3.1%INSM moved -3.32% from its $121.87 open to a $117.83 close on 2026-09-25.
- −3.2%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −4.3%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −3.2%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Insmed Incorporated (INSM) shares climbed 20.6% to $144.46 as of November 20, 2026, a sharp gain from the prior close of $119.80. BestStocks flagged the session as a major change for INSM. The move is tied to price move up. Below, we break down what changed for INSM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
INSM climbed 20.6% to $144.46
INSM climbed 20.6% in its latest session, moving from $119.80 to $144.46.
What it means for Insmed Incorporated investors
For Insmed Incorporated investors, the balance of recent signals points to a strong bullish shift. On the constructive side: Material positive event; Strong 20.6% price move with conviction. Weighing against that: New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $191.06, implying +32.3% upside from $144.46. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality medium (75/100). With earnings roughly 90 days out, the next report is the most likely near-term test of the move.
INSM price reaction
INSM last traded at $144.46, up $24.66 (+20.58%) from the previous close of $119.80. The session traded on 5.1× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $93.33 and $144.46, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Insmed Incorporated (INSM)
The consensus analyst price target on Insmed Incorporated (INSM) is $191.06, 32.3% above the recent $144.46. Over the past 90 days analysts logged 0 upgrades, 5 maintains, and 1 downgrade. Here is how the bullish and bearish cases on INSM line up.
The bullish case
- Wall Street's consensus price target of $191.06 implies +32.3% upside from $144.46.
- The Street's most bullish target is $235.00 (+62.7%).
- Material positive event.
- Strong 20.6% price move with conviction.
- Volume 5.1x average — institutional conviction.
The bearish case
- 1 analyst downgrade in the past 90 days, most recently Wolfe Research to Peer Perform (2026-10-12).
Weighing both sides, BestStocks' composite read of recent signals is strongly bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for INSM
In-depth INSM event analyses
Frequently asked questions about INSM
Why did Insmed Incorporated (INSM) stock move?
Insmed Incorporated (INSM) rose 20.6% on November 19, 2026, closing at $144.46 versus $119.80 the prior session (close-to-close, from daily closes). After Bloomberg reported that pharmaceutical giant Sanofi is exploring a potential acquisition of the company. Talks are ongoing with no guarantee of completion, but analysts estimate Insmed could command $170–$210 per share in a buyout, suggesting a 20–50% acquisition premium from the pre-announcement price. Source: FMP price data; BestStocks detection.
How much did INSM stock rise?
INSM gained 20.58% ($24.66) versus the prior close of $119.80, last trading at $144.46 on 5.1× average volume.
When is Insmed Incorporated's next earnings date?
INSM's next earnings report is estimated for 2027-02-18 — about 90 days away.
What is the analyst price target for INSM?
The consensus analyst price target for INSM is $191.06, about 32.3% above the current $144.46. Over the past 90 days, analysts recorded 0 upgrades, 5 maintains, and 1 downgrade.
How BestStocks tracks INSM
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for INSM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
